1. Introduction {#sec1}
===============

Colorectal cancer is among the top three causes of cancer mortality and is commonly diagnosed in both Western and Eastern nations, including China \[[@B1]\]. Based upon data collected in the USA and Japan, current levels of colorectal cancer reflect a sharp increase in incidence. High costs of colorectal cancer treatment have, accordingly, dramatically increased the global healthcare economic burden \[[@B2]\]. Early stage colorectal cancer can be effectively treated using advanced endoscopic procedures, including endoscopic submucosal dissection (ESD) \[[@B3]\]. ESD is a very promising approach that delivers favorable short-term outcomes. Multiple procedures can be performed simultaneously. ESD is minimally invasive and results in high radical cure rates, removal of pathological tissues, and rapid recovery \[[@B4]\]. Compared to conventional endoscopic procedures such as endoscopic mucosal resection, ESD exhibits higher*en bloc* resection rates and lower recurrence rates for early stage gastric and colorectal cancer \[[@B5], [@B28]\]. At the present time, optimized cost-benefit ratios for hospitalization time with respect to pre-ESD preparation and post-ESD complications remain undefined. To fill this knowledge gap, we performed a retrospective analysis of data collected on nearly 400 patients in order to examine the cost-effectiveness of colonic ESD.

2. Materials and Methods {#sec2}
========================

2.1. Patient Cohort {#sec2.1}
-------------------

The study is based on retrospective analysis of data from 395 patients undergoing colonic ESD between January 2015 and December 2017 at the Department of Gastroenterology, Renmin Hospital of Wuhan University, China.

2.2. Lesion and Operation Characteristics {#sec2.2}
-----------------------------------------

Tumor size (13.9 ± 2.7 mm, median 24 mm, and range from 6 to 105 mm) was included. Pathologies of the neoplasm were summarized as polyp (hyperplastic, 29, 7.3%; inflammatory, 52, 13.2%), adenoma, carcinoid, and carcinoma. Moreover, macroscopic morphology of the lesions (LST types: LST-G, 27, 6.8%; LST-NG, 37, 9.4%) was presented as well (type 0-IIc 31, 7.8%; 0-IIa+IIc, 26, 6.6%; type 0-I, 7, 1.8%). The operators consisted of junior operators and senior professors. On one hand, there were three well-trained junior doctors (trained for more than three years and operated upon more than one hundred pig stomachs and colons) who participated in the beginning steps for 72 cases that were supervised by senior professors. On the other hand, four senior professors who practiced colonic ESD for more than 500 cases and more than ten years were enrolled. The indications strictly followed the colonic ESD guidelines including polys/LST bigger than 2 cm, a submucosal tumor, carcinoid or rectal carcinoid smaller than 2 cm, and early carcinoma. The operations (techniques and procedures) were conducted according to colonic ESD guidelines, such as lesion observation, marking, submucosal injection, incision, dissection, and wound management. Complications (intraprocedural and postoperative) were involved as well.

2.3. Cost Analysis {#sec2.3}
------------------

The analyzed colonic ESD patient medical costs spanned hospital admission to discharge. Medical costs were categorized as direct, indirect, and intangible. Direct costs were related to treatment and patient care including admission, medical procedures, consumable items, medications, and nursing. Indirect costs were those ascribed to disease-related morbidity and mortality. Intangible costs encompassed nonfinancial outcomes such as pain and mental suffering. Direct medical charges were obtained from hospitalized patient charge lists (CHIS 7.0, Founder International Co., Ltd., China).

2.4. Statistical Analysis {#sec2.4}
-------------------------

Statistical analysis was performed using SPSS version 17.0 (SPSS, Chicago, IL, USA). Numerical data are presented as mean ± SD. Student\'s*t*-test was used for comparison between groups.*P*\<0.05 was considered statistically significant.

3. Results {#sec3}
==========

[Table 1](#tab1){ref-type="table"} presents clinical features and proximal outcomes for 395 patients (214 male, 185 female) between the ages of 19 and 83 years undergoing colonic ESD. The procedure duration ranged from 11 to 172 min. Tumors varied in diameter from 6 to 105 mm and were variably located from the rectum to the ascending colon. Tumors comprised polyps (20.5%), adenomas (45.3%), carcinoids (22.0%), and carcinomas (12.2%). Nine complications arose during ESD and 56 were recorded after the procedure. Postprocedure and total duration of hospital stay were also recorded.

We divided costs into several categories: hospitalization, laboratory, imaging, nursing, medication, anesthesia, consumable items, and operation. The hospital financial system precluded more specific cost stratification in this study. Total costs were divided into those covered by National Health Insurance (NHI) and those paid by the patients themselves. Operation, medication, and consumable items\' costs accounted for 71% of the total costs for colonic ESD ([Table 2](#tab2){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}).

We examined relationships between cost and lesion location. Medication and consumable items\' costs were higher for lesions in the transverse colon and right hemicolon (\>2300 USD) than for lesions in the left hemicolon (\<1900 USD). Total costs showed the same trend, with costs exceeding 6700 USD for lesions in the transverse colon and right hemicolon but less than 5800 USD for lesions in the left hemicolon. No major differences in operation costs were observed for lesions in different locations ([Table 3](#tab3){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}).

To determine the reasons for differential costs associated with different lesion locations, we examined the relationship between location and postprocedure complications. No significant differences were found for hemorrhage, perforation, or infection between different locations (*P*\>0.05). However, abdominal pain occurred significantly more frequently following procedures for lesions of the ascending and transverse colon than for other locations (*P*\<0.05) ([Table 4](#tab4){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}).

We observed that costs for medication and consumable items and total costs were significantly higher for lesions in the size ranges of 1--5 cm and \>5 cm than for lesions \<1 cm (*P*\<0.05). Operation costs, however, did not significantly differ according to lesion size (*P*\> 0.05). The presence of multiple lesions (\>1) was significantly correlated with higher costs for medication, consumable items, and operation and total costs compared to patients with a single lesion (*P*\< 0.05). Carcinoma was associated with significantly (*P*\< 0.05) higher costs for medication, consumable items, and operation and total costs compared to other pathologies ([Table 5](#tab5){ref-type="table"} and [Figure 4](#fig4){ref-type="fig"}).

Stratifying patients based on operation characteristics, we observed that positive surgical margins were associated with significantly higher medication, consumable items, and total costs compared to negative surgical margins (*P*\< 0.05). With respect to complications, hemorrhage and perforation were associated with significantly higher medication, consumable items, and total costs compared to complications of infection and abdominal pain ([Table 6](#tab6){ref-type="table"} and [Figure 5](#fig5){ref-type="fig"}).

To better understand differential costs associated with duration of hospitalization, we analyzed the occurrence of post-ESD complications. Total post-ESD complications comprised hemorrhage (6.84%, 27/395), perforation (3.54%, 14/395), infection (3.04%, 12/395), and abdominal pain (3.04%, 12/395). The incidence of complications was significantly higher within 4 d after the procedure (87.7%) than at 4 d (12.3%) ([Table 7](#tab7){ref-type="table"}). We examined costs relative to length of hospitalization (≤4 d, 4--10 d, and \>10 d). Hospitalization of ≤4 d and \>10 d was associated with the lowest and highest, respectively, medication, consumable items, and total costs (*P*\< 0.05). Hospitalization of \>10 d was correlated with significantly higher operation costs ([Table 8](#tab8){ref-type="table"} and [Figure 6](#fig6){ref-type="fig"}).

Lastly, in order to clarify the relationship between costs and outcomes, the costs have been analyzed for defined outcomes of colorectal ESD. More detailedly, the costs of uncomplicated curative ESD of cancer (and HGIN), uncomplicated noncurative ESD of cancer, and complicated ESD of cancer (and of other benign lesions) were analyzed, respectively ([Table 9](#tab9){ref-type="table"}).

4. Discussion {#sec4}
=============

Minimally invasive ESD is a promising technique for treatment of digestive tract diseases, especially polyps, adenoma, and early stage carcinoma \[[@B6]\]. Most well-trained gastrointestinal endoscopic physicians can correctly perform ESD operations \[[@B7]\]. Colonic ESD will certainly become more prevalent due to higher patient satisfaction, more comprehensive indications, shorter hospitalization times, and lower costs compared to traditional laparotomy surgery \[[@B8]\]. In China, NHI covers some costs associated with colonic ESD, except for some consumable items and medication \[[@B9]\]. The present study helps to clarify some cost issues related to colonic ESD treatment in China. More specifically, we examined costs of clinical characteristics including lesion location, size, number, and pathology; surgical margin and complications; and hospital stay after the procedure. Costs for medication and consumable items together accounted for \>60% of total costs. Operation and nursing costs combined comprised only 10% of total costs, indicating that physician and nurse labor costs in China remain low.

Nearly 90% of complications occurred within 4 d after the procedure. With respect to lesion location, abdominal pain occurred more often when lesions were located in the ascending and transverse colon. This might be due to poor gas release from high positions of the colon, with the pneumogastric nerve only exiting above the splenic flexure \[[@B10], [@B11]\]. When operating on high colonic positions surgeons generally take more time and use more consumable items (such as metal clips) to avoid complications such as hemorrhage or perforation \[[@B12]\]. In contrast, studies showed that, even in the right colon, the complication rate should not be increased for ESD on the professional level \[[@B23], [@B24]\]. This in turn requires patients to stay longer in hospital for postoperative observation \[[@B13]\]. This could contribute to higher costs for medication and consumable items and total costs for high-position colon ESD. ESD to treat larger lesions also requires more consumable items, as well as more medication to promote wound healing and patient recovery \[[@B14], [@B15]\]. We made similar observations with respect to lesion number. Some carcinoma patients received surgical and additional oncology treatment, and thus costs for these patients were relatively high \[[@B16]\]. Positive surgical margins were associated with higher medical, consumable items, operation, and total costs \[[@B17], [@B18]\]. Patients with post-ESD complications of hemorrhage and perforation had higher costs associated with repeat endoscopy and/or surgical treatment \[[@B19], [@B20]\]. Based on defined outcomes, complicated colonic ESD of cancer occupied the highest position for costs of all aspects on account of more usage of medication and consumables, more complex operations and multiple therapies intervention, and so on \[[@B21]\]. However, the uncomplicated operations had lower medication, consumable items, operation, and total costs comparing to the complicated ones. The reason might be effective coaching and cost controlling in the process. Even when well-trained junior physicians participated in some parts of an ESD operation, senior professors supervised and step-by-step guided the whole procedure \[[@B23], [@B22]\]. Further efforts (randomized control trial) could be focused on costs saving of different treatment choices, such as cost savings of professional colorectal ESD as compared to elective laparoscopic operation or surgery for a specific indication \[[@B25]\]. Our study indicated only 10.6% malignant lesions were resected by colorectal ESD. Therefore, more profound thinking should be concentrated on the endoscopic diagnosis accuracy and indication criteria selection. Cheaper techniques (e.g., EMR) should be performed for benign neoplasia \[[@B26]\]. For instance, small and rectal carcinoid could be easily resected with much cheaper procedures, such as rubber band EMR or UEMR \[[@B27]\]. Our analysis suggests benchmark costs for colonic ESD of approximately 400 USD for the procedure itself and a total treatment cost of 5000 USD. The current study retrospectively examined costs for 395 patients treated at a single center. Additional prospective multicenter studies will be needed to fully evaluate issues of cost-effectiveness.
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###### 

Clinical features and short-term outcomes for 395 patients treated with colonic ESD.

  -------------------------- ----------------------
  Age (yr)                   51.9 ± 6.7 (19--83)
  Gender                      
   Male (214)                 
   Female (181)               
  Procedure time (min)       47.7 ± 5.0 (11--172)
  Tumor size (mm)            13.9 ± 2.7 (6--105)
  Tumor location              
   Distance from anus (cm)   36.2 ± 2.9 (5--72)
  Pathology                   
  Polyp                      81 (20.5%)
   Hyperplastic              29 (7.3%)
   Inflammatory              52 (13.2%)
  Adenoma                    185 (46.9%)
  Carcinoid                  87 (22.0%)
  Carcinoma                  42 (10.6%)
  Complications               
  Intraprocedure             9 (2.3%)
   Hemorrhage                5 (1.3%)
   Perforation               3 (0.8%)
   Infection                 1 (0.2%)
   Abdominal pain            0 (0.0%)
  Postprocedure              56 (14.2%)
   Hemorrhage                22 (5.6%)
   Perforation               11 (2.8%)
   Infection                 11 (2.8%)
   Abdominal pain            12 (3.0%)
  Total                      65 (16.5%)
  Hospitalization (d)         
   Postprocedure             6.6 ± 1.0 (2--21)
   Total                     8.4 ± 1.9 (4--27)
  -------------------------- ----------------------

###### 

Medical costs by category.

  Category           USD
  ------------------ -------------------
  Hospitalization    178 (117--242)
  Laboratory         452 (395--674)
  Radiology          474 (422--790)
  Nursing            191 (163--227)
  Medication         2151 (1135--3465)
  Anesthesia         385 (352--411)
  Consumable items   1563 (1043--2667)
  Operation          433 (379--796)
  Covered by NHI     2757 (2039--3370)
  Paid by patient    3070 (2882--3496)
  Total              5927 (4615--9984)

###### 

Major costs based on lesion location.

  Classification   Rectum   Sigmoid colon   Descending colon   Transverse colon   Ascending colon   Cecum
  ---------------- -------- --------------- ------------------ ------------------ ----------------- -------
  Medication       1843     1835            1866               2397               2474              2341
  Consumable       1546     1412            1574               1801               1851              1790
  Operation        425      381             439                443                399               406
  Total            4917     4898            5755               6752               7148              6933

###### 

Complications based on lesion location.

  Complication                Location                   
  --------------------------- ---------- --- --- --- --- ---
  Hemorrhage (*n* = 27)       7          5   4   5   6   0
  Perforation (*n*= 14)       2          4   2   2   3   1
  Infection (*n* = 12)        3          4   1   2   2   0
  Abdominal pain (*n* = 12)   1          1   0   4   5   1

###### 

Main costs based on lesion size, number, and pathology.

  Category           Size (cm)   Number   Pathology                                                             
  ------------------ ----------- -------- ----------- ------------ ------------- -------- --------- ----------- -----------
                     \< 1,       1--5,    \> 5,       1, *n*=298   \>1, *n*=97   Polyp    Adenoma   Carcinoid   Carcinoma
  *n*=77             *n*=282     *n*=36   *n*=81      *n*=185      *n*=87        *n*=42                         
  Medication         1705        2249     2583        2030         2528          1909     2197      2043        3259
  Consumable items   1446        1691     1802        1419         1832          1326     1452      1465        2508
  Operation          426         430      438         421          462           397      432       450         741
  Total              5249        5921     6897        5773         6758          5674     5990      6252        9147

###### 

Main costs based on surgical margins and complications.

  Category           Surgical margin   Complication                                          
  ------------------ ----------------- -------------- ------------ ------------- ----------- ----------------
                     Negative          Positive       Hemorrhage   Perforation   Infection   Abdominal pain
  *n*=331            *n*=64            *n*=27         *n*=14       *n*=12        *n*=12      
  Medication         2012              2988           2797         3086          2490        2385
  Consumable items   1475              2460           1994         2418          1562        1649
  Operation          404               718            502          717           425         432
  Total              5626              8759           6135         8704          6056        5992

###### 

Complications based on hospitalization days after the procedure.

  Complication           Days            
  ---------------------- ------ ---- --- ---
  Hemorrhage (*n*)       5      18   1   3
  Perforation (*n*)      5      8    1   0
  Infection (*n*)        2      8    1   1
  Abdominal pain (*n*)   7      4    1   0

###### 

Costs based on hospitalization days after the procedure.

  Category           Hospitalization days (post-ESD)                      
  ------------------ --------------------------------- ------------------ --------------
                     ≤4, *n*=84                        4\<n≤10, *n*=244   \>10, *n*=67
  Medication         1835                              2479               3142
  Consumable items   1390                              1703               2004
  Operation          408                               426                579
  Total              4811                              5848               6925

###### 

Costs based on defined outcomes.

  Classification     Uncomplicated curative ESD of cancer   Uncomplicated curative ESD of HGIN   Uncomplicated noncurative ESD of cancer   Complicated ESD of cancer   Complicated ESD of other benign lesions
  ------------------ -------------------------------------- ------------------------------------ ----------------------------------------- --------------------------- -----------------------------------------
  Medication         2557                                   2213                                 2748                                      3204                        2717
  Consumable items   1640                                   1502                                 1484                                      2276                        1895
  Operation          448                                    433                                  405                                       694                         499
  Total              6348                                   6185                                 8251                                      8739                        7283

[^1]: Academic Editor: Mikihiro Fujiya
